Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-finding study of SAR442168 in relapsing multiple sclerosis
NL-OMON48153Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tolebrutinib in multiple sclerosis (MS) (4 arms), sponsored by Sanofi. Primary endpoint: Number of new gadolinium-enhancing T1-hyperintense lesions. Started Jul 2019; status: active, not recruiting.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON48153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48153.